Skip to main content
Equibles
HCWB logo

HCWB · HCW Biologics Inc. · Metrics

Track HCWB — free

Use HCWB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HCWB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.17 +0.05 (+4.46%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements, without additional funding or financial support. After considering management's plan for financing and funds raised that are probable to occur within one year, as well as that the Company expects to continue to incur losses from operations for the foreseeable future, management concluded that the substantial doubt that existed in its going concern analysis as of June 30, 2026 was not alleviated.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.15M
Shares
1.84M
Volume · Oct 23 80.64K Avg daily vol (3M) 405.37K

HCWB metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.17
Market cap
$2.15M

Price action

20 metrics
Price change (1W)
-5.6%
Price change (30D)
-35.7%
Price change (3M)
-53.2%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
112.3%
Annualized volatility (3M)
117.4%
Beta
—
RSI (14D)
28.9
Price vs SMA 50
-42.7%
Price vs SMA 200
—
Avg volume (3M)
405,367
Relative volume
0.2
Average dollar volume
$855,507

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.84M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.2×
reciprocal yield 83.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 310.2%
P / book
0.3
reciprocal yield 345.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-259.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
22.6×
reciprocal yield 4.4%
EV / revenue historical average (5Y)
18.9×
reciprocal yield 5.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-07

Profitability

9 metrics
Gross margin
96.7%
Operating margin
-115.0%
Trailing 12 months
Net margin
-83.8%
Gross profit (TTM)
$6.45M
Operating profit (TTM)
−$7.66M
Net income (TTM)
−$5.58M
Trailing 12 months
Diluted EPS (TTM)
$-21.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+1,758.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.66M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+347.6%
Year over year · more shares
Revenue CAGR (3Y)
-79.9%
Revenue CAGR (5Y)
-57.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-75.2%
Return on assets
-20.9%
Debt / equity
0.9
Current ratio
0.1
EBITDA (TTM)
−$7.06M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-13.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$5.82M
Latest balance sheet
Cash & equivalents
$741,324
Total assets
$26.77M
Total debt
$6.56M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.14M
Capital expenditures (TTM)
$0
R&D (TTM)
$5.20M
SG&A (TTM)
—
Stock compensation (TTM)
$225,913
R&D / revenue
78.0%
Stock compensation / revenue
3.4%

Ownership (13F)

9 metrics
13F filers
12
13F filer change QoQ
-3
Institutional ownership
5.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
8.3%
Private-fund adviser ownership
2.1%
Active holders' share change QoQ
+42.5%
Holder tenure
2.8
Price vs estimated holder cost
-3.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
3.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
$99,993
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1828673 CUSIP 40423R303 Visit website Investor relations